Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Front Neuroendocrinol. 2011 Nov 4;33(1):85–104. doi: 10.1016/j.yfrne.2011.10.001

Figure 2. Evidence that ERα mediates E2-induced neuroprotection in hippocampal CA1 region following ischemia.

Figure 2

(A) Western blot analysis demonstrates a robust reduction in ERα or ERβ expression after pretreatment with ERα or ERβ antisense-ODNs (AS), as compared to missense ODNs (MS) controls or Sham controls (a, b). *P < 0.05 vs. MS-treatment group, respectively. (B) Effect of MS, ERα or ERβ AS on E2 neuroprotection against cerebral ischemia. Representative CA1 sections double stained with NeuN (red) and Fluoro-Jade B (green) from E2-treated animals with ERα AS, ERβ AS or MS infusion. Note that E2 protection was abolished only in the ERα AS infused rat hippocampus (a). Values are means ± SE from 6–7 animals (b). *P < 0.05 vs. E2+MS group. Scale bar, 50 μm; Magnification, 40×; n.s., No significant difference. Figure adapted from [203].

HHS Vulnerability Disclosure